AbbVie Inc.
ABBV
Below: live stock price for AbbVie Inc. (ABBV), a 1-year chart, 8 indicators (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Volume), and a compare mode. Add to your portfolio, star to your watchlist, or set a price alert in one place.
AbbVie Inc. (ABBV) is a Healthcare company based in United States. Operating in Drug Manufacturers - General, it employs about 57,000 people. Over the past year ABBV traded between 190.75 and 291.4 USD. Trailing P/E sits near 80.63 on a market cap of about 504.37B USD. It currently yields 2.42% in dividends.
- Prev close
- $283.40
- Volume (24h)
- $1.61B
- Market cap
- $504.37B
- Currency
- USD
Score
48/ 100 · Mixed
- Value49
- Quality71
- Momentum49
- Growth72
- Risk73
- Dividend15
- Liquidity8
Composite of public market data. Informational only — not investment advice.
Trend projection
Where the recent trend points if it continues.
- +5 bars
- 287.1859 +0.62%
- +20 bars
- 289.6403 +1.48%
- +60 bars
- 290.5955 +1.81%
- +120 bars
- 290.6306 +1.83%
Linear-regression continuation — not a prediction, not investment advice. ±1σ ≈ 68% range · ±2σ ≈ 95% range: ±0.0249 USD.
Interpretation
Composite signals look mixed. Strength: risk profile with weakness: balance-sheet liquidity. Price sits near the upper third of the recent range, trend is sloping upward.
Descriptive observation — not investment advice.
Score breakdown
Raw values behind each pillar so you can see what the composite is reading.
- Value49/100
Value looks mixed — driven by P/E (80.63).
P/E:80.63PEG:0.58 - Quality71/100
Quality looks solid — driven by Gross margin (72.79%).
ROA:10.51%Profit margin:9.80%Gross margin:72.79% - Momentum49/100
Momentum looks mixed — driven by 52w change (22.99%).
52w change:22.99% - Growth72/100
Growth looks solid — driven by Earnings growth (290.40%).
Revenue growth:10.20%Earnings growth:290.40% - Risk73/100
Risk looks solid — driven by Beta (0.23).
Beta:0.23Short interest:1.02% - Dividend15/100
Dividend looks fragile — driven by Payout ratio (190.40%).
Dividend yield:2.42%Payout ratio:190.40% - Liquidity8/100
Liquidity looks fragile — driven by Current ratio (0.81).
Current ratio:0.81Quick ratio:0.49
Derived from public market data — informational, not investment advice.
Price report
How this asset has actually moved over the last 250 days.
Where the price sits between the window low and high.
- Volatility (annualised)
- 25.8%
- Max drawdown
- -16.5%
- Below period high
- -2.1%
- Best day
- +6.25%
- Worst day
- -5.20%
- Up days
- 51%
- Current streak
- 1 up
- Typical day swing
- 2.3%
- Volume vs average
- +13%
Spread of returns. Higher means larger swings in both directions.
Worst peak-to-trough fall inside the window.
Current price against the highest point in the window.
Share of days that closed above the one before.
Average high-to-low spread within a single day.
Last 10 days against the whole window.
Descriptive statistics over past prices — not a forecast and not investment advice.
Reference levels
Fibonacci retracements and extensions across the recent range.
Reference only — not investment advice.
These coordinates describe past-trade clustering, not where to buy or sell. Do your own research before any trade.
Levels derived from: 291.4 high → 241.2 low · 60 bars
- ResistanceFib +161.8% extensionnot reached372.6236 USD+30.55% from current
- ResistanceFib +100% extensionnot reached341.6 USD+19.68% from current
- ResistanceFib +61.8% extensionnot reached322.4236 USD+12.96% from current
- ResistanceFib +27.2% extensionnot reached305.0544 USD+6.88% from current
- Current285.42 USD
- SupportFib 23.6% retracementNearesttested 3×279.5528 USD-2.06% from current
- SupportFib 38.2% retracementtested 3×272.2236 USD-4.62% from current
- SupportFib 50% midpointtested 15×266.3 USD-6.70% from current
- SupportFib 61.8% retracementtested 13×260.3764 USD-8.77% from current
- SupportFib 78.6% retracementtested 5×251.9428 USD-11.73% from current
- SupportFib −27.2% extensionnot reached227.5456 USD-20.28% from current
- SupportFib −61.8% extensionnot reached210.1764 USD-26.36% from current
- SupportFib −100% extensionnot reached191 USD-33.08% from current
How to read this
We take the highest and lowest price of the last 60 bars and cut the gap between them at the classic Fibonacci ratios (23.6%, 38.2%, 50%, 61.8%, 78.6%), plus extensions beyond both ends.
“Tested N×” counts how many of those 60 bars actually traded through the level. A level price has crossed many times is one the market has repeatedly agreed on; a level at 0 is pure geometry the price has never reached.
This is a map of where trading has already happened — not a forecast and not a signal. Price moves through these levels all the time.
Financials
- 52w high
- $291.40
- 52w low
- $190.75
- 52w change
- 22.99%
- Day high
- $286.64
- Day low
- $283.00
- P/E (TTM)
- 80.63
- Forward P/E
- 17.6
- PEG
- 0.58
- Beta (5Y)
- 0.23
- Enterprise value
- 568.73B
- EV / Revenue
- 8.83
- EV / EBITDA
- 18.49
- EPS (TTM)
- $3.54
- Forward EPS
- $16.21
- Dividend yield
- 2.42%
- Dividend rate
- $6.92
- Payout ratio
- 190.40%
- Revenue (TTM)
- 64.39B
- EBITDA
- 30.76B
- Free cash flow
- 16.87B
- Total cash
- 6.57B
- Total debt
- 70.88B
- Current ratio
- 0.81
- Quick ratio
- 0.49
- Profit margin
- 9.80%
- Gross margin
- 72.79%
- Return on assets
- 10.51%
- Shares outstanding
- 1.77B
- Float
- 1.76B
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Analyst & Risk
- Beta (vs S&P 500)
- 0.23
- very stable
- 52-week change
- 22.99%
- Short % of float
- 1.02%
- Short ratio (days)
- 3.93
- Current ratio
- 0.81
- Quick ratio
- 0.49
- ROA
- 10.51%
- PEG ratio
- 0.58
- potentially undervalued
- EV / Revenue
- 8.83
- EV / EBITDA
- 18.49
- Revenue growth
- 10.20%
- Earnings growth
- 290.40%
- EBITDA
- 30.76B
- Free cash flow
- 16.87B
- Total cash
- 6.57B
- Total debt
- 70.88B
- Insider holdings
- 0.11%
- Institutional
- 77.33%
Recent rating changes
- 2026-10-13RBC CapitalOutperform → Outperformreit
- 2026-10-09UBSNeutral → Neutralmain
- 2026-10-09GuggenheimBuy → Buyreit
- 2026-10-08JP MorganOverweight → Overweightmain
- 2026-10-08Cantor FitzgeraldOverweight → Overweightmain
- 2026-10-07Morgan StanleyOverweight → Overweightmain
- 2026-10-06ScotiabankSector Outperform → Sector Outperformmain
- 2026-09-10HSBCBuy → Buymain
Financial documents
- Corporate Changes & Voting Matters8-K2026-10-15
- Corporate Changes & Voting Matters8-K2026-10-05
- Corporate Changes & Voting Matters8-K2026-09-03
- Corporate Changes & Voting Matters8-K2026-08-18
- Corporate Changes & Voting Matters8-K2026-08-05
- Periodic Financial Reports10-Q2026-08-03
- Corporate Changes & Voting Matters8-K2026-07-31
- Corporate Changes & Voting Matters8-K2026-07-06
- Annual report of employee stock purchase11-K2026-06-24
- Corporate Changes & Voting Matters8-K2026-06-22
- Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)SD2026-06-01
- Corporate Changes & Voting Matters8-K2026-05-12
Recent news
- /C O R R E C T I O N - AbbVie/PR Newswire3h ago
- AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor PortfolioPR Newswire3h ago
- AbbVie’s Dividend Keeps Climbing. Is It Still a Buy for Income Investors?24/7 Wall St.1d ago
- Forget High-Yield Traps: AbbVie Is the Dividend King to Buy and Hold Through Any Rate CycleMotley Fool1d ago
- SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026PR Newswire1d ago
- What AbbVie (ABBV)'s Phase 3 Lymphoma Win Means For ShareholdersSimply Wall St.1d ago
- What Was Eli Lilly Telling You Before Its Stock Ran?Trefis1d ago
- When Amgen's Forecast And Chart Say The Same Thing, Pay AttentionTrefis2d ago
Related
Other assets in this category.
- 8306.TMitsubishi UFJ Financial Group, Inc.3,431 USD-1.27%
- 7203.TToyota Motor Corporation3,075 USD-0.61%
- 9984.TSoftBank Group Corp.4,732 USD-4.29%
- 6758.TSony Group Corporation3,946 USD-0.33%
- 6861.TKeyence Corporation79,950 USD-1.00%
- NVDANVIDIA Corporation214.13 USD-1.43%
- AAPLApple Inc.343.46 USD+0.43%
- GOOGLAlphabet Inc.340.59 USD-2.47%
Learn the terms
Live discussion
Sign in to join the discussion.
- No comments yet. Be the first.